The study was led by Kimberly A. Bertrand of the Slone Epidemiology Center at Boston University and Boston University Chobanian & Avedisian School of Medicine, together with colleagues including Julie R. Palmer and Catharine Wang. It drew its participants from the Black Women’s Health Study (BWHS), a landmark cohort established in 1995 among respondents to a mailed questionnaire sent to subscribers of Essence magazine and members of selected Black professional organizations. The new analysis is embedded within a randomized controlled trial of alternate disclosure modalities for returning individual-level cancer genetic research results to participants whose DNA had been sequenced as part of a nested case-control study on the genetic etiology of breast cancer.

Of 2,670 eligible women invited to enroll in the parent trial, 927, or 35 percent, consented and completed a baseline questionnaire in 2023 and early 2024. Because the participants had been selected for a case-control study of breast cancer genetics, nearly one-third of the sample, 273 women or 29 percent, had a personal history of breast cancer. Mean age was 67.5 years among survivors and 66.4 years among women without breast cancer. The cohort was highly educated, with more than 65 percent of both groups holding a college degree or higher, and 98 percent reported having health insurance. Nearly 40 percent of the breast cancer survivors reported having had prior genetic testing for cancer, compared with just 3.7 percent of women without a cancer history, a difference the researchers considered when interpreting their results.

The questionnaire assessed three distinct psychological and cognitive constructs. Knowledge was measured as the sum of correct answers to 16 true/false statements adapted from previously validated measures, covering factual understanding of genetics, the genetic risk of cancer, patterns of inheritance, and the clinical and legal implications of genetic testing. Missing responses were coded as incorrect. Attitudes toward testing were captured with a three-item scale measuring perceived benefits, with statements such as “Genetic testing will help me manage my cancer risk” rated on a five-point agreement scale; the scale showed good internal consistency with a Cronbach’s alpha of 0.74. Self-efficacy, defined as confidence in one’s ability to use genetic information, was assessed with a four-item adapted scale featuring statements such as “I have a good idea about how genetics may influence risk for disease generally,” with a Cronbach’s alpha of 0.79. The team then used multivariable linear regression to identify individual-level predictors of each construct, adjusting for age, education, marital status, personal and family cancer history, and prior genetic testing.

The headline result was striking for its uniformity. Overall, mean knowledge score was 12.4 out of 16, equivalent to 77 percent correct, and there was essentially no difference between women with a history of breast cancer, who averaged 12.5 points, and those without, who averaged 12.3. Thirteen of the sixteen questions were answered correctly by at least 70 percent of participants. The authors noted this was somewhat unexpected, since one might assume that women who had undergone cancer treatment, many of whom had been offered genetic testing themselves, would outperform their peers. Instead, the data suggest that the fundamental concepts of hereditary cancer risk have permeated broadly across this population rather than concentrating among those with direct clinical experience.

Yet the item-level analysis revealed precisely where the gaps lie, and the pattern is clinically meaningful. Only 62.8 percent of women without breast cancer and 72.9 percent of those with breast cancer correctly answered “false” to the statement “Most cancer is caused by inherited gene mutations,” indicating that a substantial minority still overestimate the role of inherited mutations in cancer causation. Roughly 43 percent incorrectly believed that “a genetic test can always determine if an individual has a cancer gene mutation,” a misconception about the limitations of testing that could inflate expectations and fuel disappointment or mistrust after a negative result. The most striking deficit concerned variants of uncertain significance, or VUS, a category of genetic finding that has become one of the most common results returned by modern multigene panel testing. Just 31.5 percent of survivors and 27.4 percent of women without breast cancer correctly indicated “false” to the statement “A Variant of Uncertain Significance will usually influence cancer screening recommendations.” In other words, roughly seven in ten participants did not understand that a VUS is an ambiguous finding that generally should not change medical management, a misunderstanding with real potential to drive unnecessary anxiety or inappropriate screening decisions.

The regression models added texture to these findings. Knowledge scores declined by 0.5 points for every 10-year increase in age, and women with 17 or more years of education scored 1.7 points higher than those with 12 or fewer years. Women who were separated, divorced, or widowed scored somewhat lower than those who were married or living as married, a difference the authors suggest may reflect more limited social support or economic instability. Having had prior genetic testing was associated with a 0.66-point higher knowledge score, though the researchers caution that the direction of causality is unclear; greater knowledge may have motivated testing rather than the reverse.

Attitudes and self-efficacy told an equally important story. Mean attitude scores, on a five-point scale, were 4.2 among survivors and 4.0 among women without breast cancer, while mean self-efficacy scores were 3.9 and 3.8 respectively, both indicating strongly favorable dispositions. Personal breast cancer history was associated with slightly more favorable attitudes, as was a first-degree family history of breast cancer. Older age and never having been married were associated with less favorable attitudes. Self-efficacy rose with education, with a first-degree family history of cancer, and, notably, with total knowledge score, suggesting that knowledge itself may feed confidence in the ability to act on genetic information.

For the authors, these findings carry a pointed implication for the debate over why Black Americans engage with cancer genetic testing at far lower rates than non-Hispanic White individuals, even when referred for testing. Black women’s mortality from breast cancer, the most common cancer in women across all racial and ethnic groups, is nearly 40 percent higher than that of White women, and Black individuals consistently report lower uptake of germline testing. Previous research has implicated system-level and provider-level factors, including access to specialists, clinical workflows, biases in physician referral practices, and health care segregation, as well as individual-level factors such as medical mistrust and concerns about genetic discrimination. But if knowledge is high and attitudes are favorable, as this study suggests, then deficits in patient knowledge and negative beliefs are unlikely to be the principal drivers of the disparity. The authors argue that addressing system-level barriers will be critical to improve cancer outcomes among Black women.

The study does have limitations that the researchers themselves acknowledge. The participants, drawn from a cohort that has been engaged in health research for nearly three decades, are unusually educated and health-literate, so the findings may not generalize to less educated populations, and the high baseline scores raise the possibility of a ceiling effect that could have masked true differences between groups. Still, the sample size makes this one of the largest investigations of cancer genetics knowledge and attitudes among Black women to date, and the comprehensive assessment of knowledge, attitudes, and self-efficacy using measures adapted from published literature strengthens its conclusions.

The practical upshot is a roadmap for targeted education. Older women, those with lower educational attainment, women who are not married or living as married, and, counterintuitively, breast cancer survivors themselves all emerged as groups that could benefit from focused messaging, particularly around the inherited etiology of cancer, the limitations of genetic tests, and the meaning of variants of uncertain significance. At the same time, the study affirms that when the doors to genetic testing are opened, Black women arrive with the knowledge and the motivation to walk through them. The barriers, the evidence increasingly suggests, are built into the system, not the patient.

Multiple myeloma, characterized by malignant plasma cell proliferation, is notorious for its debilitating symptoms and varied treatment side effects, which collectively erode patient quality of life. While prior investigations have predominantly focused on populations in high-income countries, there has been a glaring paucity of robust data from low- and middle-income regions. This research addresses that knowledge gap by deploying the validated Arabic version of the EORTC QLQ-MY20 questionnaire, tailored for assessing QoL in myeloma patients, thereby ensuring culturally sensitive and reliable patient-reported outcomes in a Middle Eastern context.

The study dissects quality of life into distinct subscales, emphasizing the “Side Effects of Treatment,” “Body Image,” and “Future Perspective,” to delineate nuanced patient experiences. Notably, patients experiencing abdominal pain, chest pain, and swelling reported markedly worse scores on the side effects subscale. These symptoms emerged as independent predictors of diminished QoL even after adjusting for various clinical and demographic variables, underscoring their dominant role in patients’ lived experiences during therapy.

Abdominal pain, a frequently reported complaint in MM, likely reflects gastrointestinal and systemic complications related to both disease pathology and treatment toxicities. Chest pain and swelling similarly signal distressing cardiopulmonary and vascular sequelae, which not only inflict physical burden but may also amplify psychological strain. The statistically significant beta coefficients associated with these symptoms confirm their robust negative influence, an insight that demands urgent clinical attention.

Beyond symptomatic anguish, the study highlights the formidable shadow cast by comorbid conditions such as gout and peptic ulcer disease on patients’ body image—a crucial psychological facet influencing self-esteem and social functioning. These comorbidities showed a pronounced detrimental effect, revealing for the first time how concurrent autoimmune and gastrointestinal disorders intersect with cancer-related distress to compound patients’ suffering.

Serum calcium levels also demonstrated a borderline effect on body image perceptions, hinting at possible biochemical pathways through which metabolic abnormalities might erode psychological health. The biochemical milieu in multiple myeloma patients is notoriously dysregulated, with hypercalcemia known to exacerbate systemic symptoms, potentially influencing mood and cognitive function.

When exploring patients’ outlook on their futures, chest pain again surfaced as a borderline negative predictor. While less pronounced than in the side effects domain, this finding suggests that persistent cardiopulmonary discomfort may color patients’ hopefulness and their capacity to envisage life beyond illness. The psychological burden intertwined with physical symptoms calls for integrated care that addresses both mind and body.

The robustness of these conclusions is bolstered by advanced multivariate statistical techniques. Employing LASSO (Least Absolute Shrinkage and Selection Operator) variable selection minimized multicollinearity and overfitting, sharpening the identification of stable, predictive variables. This methodological rigor lends credence to the explanatory power of the symptom and comorbidity models, which accounted for 25.9% of variance in side effects, 10.5% in body image, and 2.4% in future perspective subscales respectively.

These findings bear critical implications for healthcare systems, particularly in resource-constrained environments such as Palestine, where the integration of personalized supportive care remains an ongoing challenge. The recognition of specific symptom burdens and comorbidities as key determinants of quality of life underscores the necessity for tailored symptom management strategies—ranging from effective pain control and gastroprotective therapies to management of metabolic derangements and psychological support services.

Moreover, this study illuminates the complex interplay between physical ailments and psychological resilience in cancer care. The interplay between bodily symptoms, comorbidities, and patient perception beckons a holistic, multidisciplinary approach that transcends conventional oncologic treatment paradigms. Healthcare providers in similar settings must be vigilant in screening for and addressing these determinants to mitigate the multidimensional impact of MM.

Given the increasing incidence of multiple myeloma worldwide and its rising burden in developing regions, the study’s culturally contextualized data is invaluable for global oncology. It fills a critical void, offering evidence-based roadmaps for clinicians, policymakers, and patient advocates to enhance quality of life through integrated, symptom-focused interventions that acknowledge regional healthcare limitations.

Beyond the immediate clinical implications, these findings propel future research directions aimed at elucidating mechanistic links between treatment side effects, comorbidities, and psychosocial outcomes. Longitudinal studies that track symptom trajectories and their molecular correlates could unlock personalized therapeutic strategies, maximizing efficacy while minimizing quality of life compromises.

Importantly, this study galvanizes the research community to prioritize patient-reported outcomes as key metrics in oncology trials and practice, reinforcing that survival gains must be balanced with meaningful improvements in daily living and psychological well-being. The data also stresses the importance of addressing comorbid conditions in cancer care protocols, an area often overlooked in the quest to control tumor progression.

The message resonates beyond the clinic, serving as a clarion call for advocacy focused on resource allocation and healthcare infrastructure improvements in underserved communities. It champions a patient-centered paradigm where quality of life is not secondary to survival, but a primary outcome driving compassionate, comprehensive cancer care.

In summary, this thorough investigation by Abu Hamdeh and colleagues illuminates pivotal predictors shaping quality of life in multiple myeloma patients within a Middle Eastern healthcare context. By meticulously unraveling the roles of abdominal pain, chest pain, swelling, gout, and peptic ulcer disease across QoL dimensions, the study forges a crucial link between symptom management and patient well-being that could transform supportive care frameworks globally. Its integration of culturally appropriate tools and advanced analytics stands as a model for future cancer QoL research worldwide.

Subject of Research: Quality of life predictors in multiple myeloma patients in low-resource settings

Article Title: Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study

Article References:
Abu Hamdeh, N., Alnees, M., Ewidat, O. et al. Predictors of quality of life in multiple myeloma patients: a multi-centered cross-sectional study. BMC Cancer 25, 1472 (2025). https://doi.org/10.1186/s12885-025-14960-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14960-w